ToxTracker is an in vitro method that accurately predicts genotoxicity without the use of animals. The results constitute an essential part of the approval process by the OECD for international acceptance of novel methods by regulatory authorities.
The evaluation was finalized earlier in the year and data have been submitted to the OECD showing that ToxTracker consistently demonstrates high accuracy and excellent reproducibility of test results, both within and between different laboratories. These data prove that ToxTracker is both robust and reliable. Importantly, ToxTracker can provide insight into the mode of action of genotoxic compounds thereby significantly improving the in vitro safety assessment of novel pharmaceutical products, chemicals, cosmetics and food-related products.
Visit the page below for the full press release and a link to the publication:
Toxys publication on OECD ring trial validation of ToxTracker
As of June, the Leiden Bio Science Park team has been joined by Gerwin Zomer, who steps into the role of Account Manager Physical Living Environment. To get to know him a bit...
Researchers at the Leiden University Medical Center (LUMC) have announced promising early results from a clinical trial using lab-grown insulin-producing islet cells derived from...
VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.